Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS-Specific Autologous TCR-T Cells in Advanced Solid Tumors
NCT06767046Phase 1Active, not recruiting
- Sponsor
- CorreGene
- Start
- Feb 2025
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRTKVA11 in solid tumor, colorectal cancer (CRC), pancreatic cancer (PC) and 1 more, sponsored by CorreGene. Primary endpoint: Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs) at 2 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
CRTKVA11
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06767046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767046.